Latest filing published 03 Sept 2026 for Kiniksa Pharmaceuticals International, plc, €1.0M. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Sanj K. Patel is a declared insider of Kiniksa Pharmaceuticals International, plc (chief executive), with filings sourced from SEC (Form 4). In total, 64 filings cover trades dated from 29 May 2018 to 1 September 2026.
Every open-market trade on record is a sale: 18 sales worth €33.7M. Other entries cover 4 share grants and 40 option exercises. So far in 2026, the count stands at no purchases and 8 sales.
The record was last updated on 3 September 2026 with an option exercise in Kiniksa Pharmaceuticals International, plc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 56 declarations